Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma

BJU International

Volumn 98, Issue 2, 2006, Pages 335-340

  Denberg, Thomas D ^a,c   Glodé, L Michael ^a   Steiner, John F ^a   Crawford, E David ^a   Hoffman, Richard M ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Health disparities; Locally advanced disease; Marriage; Prostate cancer; Treatment patterns

Indexed keywords

ANTIANDROGEN;

ADULT; ADVANCED CANCER; AGE; AGED; AGGRESSIVE LOCAL THERAPY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER REGISTRY; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DEMOGRAPHY; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE DISTRIBUTION; HISPANIC; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RACE; RISK ASSESSMENT; SOCIAL ASPECT;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 33745712550     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06260.x     Document Type: Article

References (20)

1. Pilepich MV, Krall JM, al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma. a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-23
2. Syed S, Petrylak DP, Thompson IM. Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches. Urol Oncol 2003; 21: 235-43
3. Seidenfeld J, Samson DJ, Aronson N et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999; 4: 1-246
4. National Cancer Institute. Stage III Prostate Cancer. Prostate Cancer PDQ®: Treatment, December 8, 2005. Available at: http://www.nci.nih.gov/ cancertopics/pdq/treatment/prostate/HealthProfessional/page7. Accessed March 2006
5. Southwest Oncology Group. S9921 - Phase III intergroup. Adjuvant androgen deprivation versus mitoxantrone plus prednisone plus androgen deprivation in selected high risk prostate cancer patients following radical prostatectomy, phase III, 1999. Available at: http://www.swog.org/Visitors/ViewProtocolDetails. asp?ProtocolID=64. Accessed March 2006
6. Department of Veterans Affairs. CSP #553 Chemotherapy after prostatectomy (CAP) for high risk prostate carcinoma. A phase III randomized study. Clinical Trials.gov identifier: NCT00132301. Available at: http://www.clinicaltrials.gov/ ct/show/NCT00132301. Accessed March 2006
7. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997; 32: 385-90
8. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 2000; 38: 372-9
9. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690-1
10. Denberg TD, Beaty BL, Kim FJ, Steiner JF. Marriage and ethnicity predict treatment in localized prostate carcinoma. Cancer 2005; 103: 1819-25
11. Hoffman RM, Harlan LC, Klabunde CN et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med 2003; 18: 845-53
12. Jancin B. Radiation improves advanced prostate cancer's outcomes. In Internal Medicine News, Vol. 38 (22). Morristown, NJ: Elsevier, 2005: 1, 6
13. Powell IJ, Tangen CM, Miller GJ et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 2002; 168: 2016-9
14. Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167: 112-6
15. Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002; 90: 561-6
16. Bono AV, Pagano F, Montironi R et al. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology 2001; 57: 117-21
17. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6
18. Akakura K, Isaka S, Akimoto S et al. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999; 54: 313-8
19. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 2005; 128: 819-24
20. Movsas B, Hanlon AL, Pinover W, Hanks GE. Is there an increased risk of second primaries following prostate irradiation? Int J Radiat Oncol Biol Phys 1998; 41: 251-5